The use of ustekinumab in a patient with severe psoriasis and positive HBV serology

Anais Brasileiros de Dermatologia

Raquel Bissacotti Steglich¹  Luana Pizarro Meneghello¹  André Vicente Esteves De Carvalho¹  Hugo Cheinquer¹  Fernanda Melo Muller¹  Flávia Pereira Reginatto¹ 

关键词: Hepatitis B;    Hepatitis B virus;    Psoriasis;   

DOI  :  10.1590/abd1806-4841.20143013

来源: SciELO

【 摘 要 】

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the world's population. Immunobiological medications are prescribed for certain patients with severe forms of psoriasis, however, these drugs increase the risk of reactivation of viral diseases such as hepatitis B. We report the case of a patient with severe psoriasis with positive serology for the Hepatitis B virus, who received ustekinumab (a human monoclonal antibody against interleukin 12 and 23). In this patient, the use of ustekinumab did not reactivate the Hepatitis B virus. Given the high prevalence of chronic viral infections in patients who are candidates for biologic therapy, as well as the potential for reactivate chronic viral illness, randomized controlled studies are needed to assess the risks and benefits of such therapy in these populations.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License